Gelesis Holdings, Inc.
GLSNYSEHealthcare
$0.16
+$0.00(+0.00%)
Market Cap$11630550
P/E Ratio—
52W High$5.67
52W Low$0.012
Gelesis Holdings, Inc.（GLS）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · GLS · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 |
|---|---|---|
| Revenue | ||
| Revenue | $25.77M | $11.19M |
| Cost of Revenue | $27.56M | $9.98M |
| Gross Profit | ($1.79M) | $1.20M |
| Gross Margin %(computed) | -6.95% | 10.75% |
| Operating Expenses | ||
| R&D Expenses | $18.61M | $12.87M |
| G&A Expenses | $42.21M | $18.26M |
| Total Operating Expenses | $120.02M | $86.17M |
| Operating Income | ($121.81M) | ($84.97M) |
| Operating Margin %(computed) | -472.72% | -759.70% |
| Interest Income | $0.00M | $0.00M |
| Interest Expense | $0.99M | $1.36M |
| Income Before Tax | ($55.30M) | ($93.33M) |
| Income Tax Expense | $0.48M | $0.02M |
| Net Income | ($55.78M) | ($93.35M) |
| Net Margin %(computed) | -216.48% | -834.57% |
| Per Share & EBITDA | ||
| EPS (Basic) | $-0.79 | $-16.34 |
| Wtd Avg Shares | 70.30M | 5.71M |
| EBITDA | ($121.81M) | ($80.53M) |
| EBITDA Margin %(computed) | -472.72% | -719.97% |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Gelesis Holdings, Inc.
关于Gelesis Holdings, Inc.（GLS）损益表
Gelesis Holdings, Inc.（GLS）损益表数据来源于SEC Form 10-K及10-Q申报文件。2022财年，GLS实现营收$0.03B，毛利润($0.00B)（毛利率-6.95%），净利润($0.06B)（净利率-216.48%）。
常见问题
GLS · 4 问Gelesis Holdings, Inc.（GLS）2022财年营收为$0.03B，同比up130.4%。
GLS revenueGLS salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09